A Phase I Study of AG-270 for Patients with Advanced Solid Tumors and Lymphoma

Full Title

A Phase 1 Study of AG-270 in the Treatment of Subjects with Advanced Solid Tumors or Lymphoma with Homozygous Deletion of MTAP

Purpose

The purpose of this study is to find the highest dose of the investigational drug AG-270 that can be given safely in patients with advanced lymphoma or solid tumors that continue to grow despite standard treatment or for which no standard treatment exists. AG-270 is being evaluated in patients whose cancers have lost a protein called methylthioadenosine phosphorylase (MTAP). The MTAP gene is often lost along with another common gene called CDKN2A (or p16). In laboratory studies, tumor cells with loss of the MTAP gene shrank or stopped growing when treated with AG-270. AG-270 is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have advanced lymphoma or solid tumors that continue to grow despite standard treatment or for which no standard treatment exists.
  • Patients’ cancers must have loss of the CDKN2A gene (p16) or MTAP.
  • Patients must recover from the serious side effects of prior therapies before entering the study.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Mrinal Gounder at 646-888-4167.

Protocol

18-198

Phase

I

Investigator

Co-Investigators

Diseases